LOBEF

12-month data confirming that L-130 is the first reported stable oral psilocinFirst-in-Man clinical data demonstrates the superior PK profile of L-1302023 sales of $1.1M (CAD) for Altemia®VANCOUVER, British Columbia, January 08, 2024--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focu... Read More...

L-130 passes 12 months ongoing stabilityVANCOUVER, British Columbia, December 05, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilize... Read More...

VANCOUVER, British Columbia, September 18, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Of... Read More...

First-in-Man trial for Lobe’s proprietary stabilized psilocin analogueAll subjects dosed with no significant adverse events to dateVANCOUVER, British Columbia, June 27, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare dis... Read More...

Phillips also named President of Altemia & Co., a Lobe Sciences CompanyVANCOUVER, British Columbia, June 07, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxter Phillips... Read More...

Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe’s Novel Sickle Cell Anemia Medical FoodVANCOUVER, British Columbia, May 17, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases t... Read More...

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Bran... Read More...

Dosing In Human Clinical Trial To Commence Within WeeksVancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that its e... Read More...

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of USD $250,... Read More...

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible n... Read More...

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other init... Read More...

Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd... Read More...

Vancouver, British Columbia--(Newsfile Corp. - February 14, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 11, 2022, it sold 8,000,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer ... Read More...